Review
References
Acton N, Roth RJ (1992). On the conversion of dihydroartemisinic acid into artemisinin. J. Org. Chem., 57: 3610-3614. |
|
|
|
Basco LK (2004). Molecular Epidemiology of Malaria in Cameroon. XIX. Quality of Antimalarial Drugs Used for Self-medication. Am. J. Trop. Med. Hyg., 70(3): 245-250. |
|
|
|
Bloland P (2001). Drug Resistance in Malaria. A Background Document for the WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva: World Health Organization. |
|
|
|
Bosman A, Mendis KN (2007). A major Transition in Malarial Treatment: The adoption and deployment of Artemisinin-based combination Therapies. Am. J. Trop. Med. Hyg., 77(6): 193-197. |
|
|
|
Covello PS, Teoh KH, Polichuk DR, Reed DW, Nowak G (2007). Functional genomics and the biosynthesis of artemisinin. Phytochem., 6814 : 1864-1871. |
|
|
|
Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO (2003). Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol., 64: 382-394. |
|
|
|
Elamin SB, Malik EM, Abdelgadir T, Khamiss AH, Mohammed MM, Ahmed ES, Adam I (2005). Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Malaria J., 4: 41. |
|
|
|
Eline KJM, Nahlen B, Wardlaw T, Young M (2005). World Malaria Report: World Health Organization (WHO), Roll Back Malaria (RBM) and United Nations Children's Fund (UNICEF). Geneva: World Health Organization. |
|
|
|
Firestone G (2006). Artemisinin Disrupts Estrogen Receptor-Alpha and Cell Growth.Carlifornia Breast cancer Research Program. |
|
|
|
Firestone GL, Sundar SN (2009). Anticancer activities of artemisinin and its bioactive derivatives. Expert. Rev. Mol. Med., 11:e32. |
|
|
|
Gao N, Budhraja A, Cheng S, Liu EH, Huang C, Chen J, Yang Z, Chen D, Zhang Z, Shi X (2011). Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis. 16(5): 511-523. |
|
|
|
Grupper M (2005). Meeting on the Production of Artemisinin and ACTs. Arusha, Tanzania: DFID Health Resource Centre, Roll Back Malaria, World Health Organization. |
|
|
|
Hamm S (2009). Crative Capitalism' versus Malaria. Business Week. 083. |
|
|
|
Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O (2005). Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet, 366: 1960-1963. |
|
|
|
Jansen FH (2006). The herbal tea approach for artemesinin as a therapy for malaria? Trans R Soc Trop. Med. Hyg., 100(3): 285-286. |
|
|
|
Lefevre G, Looareesuwan S, Treeprasertsuk S (2001). A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg., 64(5-6): 247-256. |
|
|
|
Li J, Zhou B (2010). Biological Actions of Artemisinin: Insights from Medicinal Chemistry Studies. Molecule, 15(3): 1378-1397. |
|
|
|
Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J (2008). Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol. Ther., 7: 1017-1023. |
|
|
|
Martin VJ, Yoshikuni Y Keasling JD (2001). The in vivo synthesis of plant sesquiterpenes by Escherichia coli. Biotech. Bioeng., 7: 497-503. |
|
|
|
Miller LH, Baruch DI, Marsh K, Doumbo OK (2002). The pathogenic basis of malaria. Nature 415: 673-679. |
|
|
|
Mutabingwa TK, Anthony D, Heller A (2005). Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365(9469): 1474-1480. |
|
|
|
Ohgami Y, Elstad CA, Chung E, Shirachi DY, Quock RM, Lai HC (2010). Effect of Hyperbaric Oxygen on the Anticancer Effect of Artemisinin on Molt-4 Human Leukemia Cells. Intl. J. Cancer Res. Treatment. 30(11): 4467-4470. |
|
|
|
Olumese P (2006). Guidelines for the Treatment of Malaria. Geneva: World Health Organization. |
|
|
|
Parker MH, Northrop J, Elias J, Ploypradith S, Xie P, Shapiro S, Theresa A (1999). Orally Active, Hydrolytically Stable, Semisynthetic, Antimalarial Trioxanes in the Artemisinin Family. J. Med. Chem., 42 (2): 300-304. |
|
|
|
Ramacher M, Umansky V, Efferth T (2009). Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. Anti-Cancer Drugs. 20(10): 910-917. |
|
|
|
Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, Ho KA, Eachus RA, Ham TS, Kirby J, Chang MC, Withers ST, Shiba Y, Sarpong R, Keasling JD (2006). Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440: 940-943. |
|
|
|
Rowen RJ (2009). Artemisinin: From Malaria to Cancer Treatment. Wikipedia encyclopaedia. http://en.wikipedia.org/wiki/Artemisinin. (3-12-2011). |
|
|
|
Sarpong R, Keasling JD (2006). Production of the antimalarial drug precursor artemisinic acid in engineered yeast Nature. 440: 940-943. |
|
|
|
Schmid G, Hofheinz W. (1983). Total Synthesis of qinghaosu J. Am. Chem. Soc., 105(3): 624-625. |
|
|
|
Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GA (2005). Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med., 2: e92. |
|
|
|
Vugt MV, Wilairatana P, Gemperli B (1999). Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg., 60(6): 936-942. |
|
|
|
Wikipedia (2011). Isopentenyl pyrophosphate. http://en.wikipedia.org/wiki/Isopentenyl_pyrophosphate. (3-12-2011). |
|
|
|
World Bank (2003). Report of the Expert Consultation on the Procurement & Financing of Antimalarial Drugs . Washington D.C. |
|
|
|
World Health Organization. (2001b). Antimalarial drug combination therapy: Report of WHO technical consultation . Geneva, World Health Organization (WHO/CDS/RBM/2001.35). |
|
|
|
World Health Organization. (2003). Procurement, quality and sourcing project: access to artemisinin-based combination antimalarial drugs of acceptable quality. Geneva, World Health Organization. |
|
|
|
World Health Organization (2008). WHO ultimatum on artemisinin monotherapy is showing results. http://www.bmj.com/cgi/content/full/332/7551/1176-b. (3-12-2011). |
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0